Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab vs. Chemotherapy as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

Background: The CheckMate 227 trial has indicated that nivolumab plus ipilimumab compared with chemotherapy significantly increases long-term survival in the first-line setting of advanced non-small-cell lung cancer (NSCLC). Methods: A Markov model was built to estimate the cost and effectiveness of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Huabin, She, Longjiang, Liao, Mengting, Shi, Yin, Yao, Linli, Ding, Dong, Zhu, Youwen, Zeng, Shan, Carbone, David P., Huang, Jin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507990/
https://www.ncbi.nlm.nih.gov/pubmed/33014826
http://dx.doi.org/10.3389/fonc.2020.01649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507990/
https://www.ncbi.nlm.nih.gov/pubmed/33014826
http://dx.doi.org/10.3389/fonc.2020.01649

Ejemplares similares